FDA Approves Gavreto for Treatment of RET-Positive, Metastatic NSCLC

The FDA granted accelerated approval to pralsetinib (Gavreto, Blueprint Medicines) for adults with metastatic RET fusion–positive non-small cell lung cancer (NSCLC) detected by an FDA-approved test. “Targeted therapies have dramatically improved care for patients with non-small cell lung cancer driven by oncogenes, including EGFR and ALK, and the approval of the selective Read more…